A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer\'s disease.
Epistemonikos ID: 4e660505022022012fe30eb3ea86337a88ad4ae0
First added on: May 06, 2024